Literature DB >> 12093302

Limitations of the methods used for calculating quality-adjusted life-year values.

Gérard Duru1, Jean Paul Auray, Ariel Béresniak, Michel Lamure, Abby Paine, Nicolas Nicoloyannis.   

Abstract

OBJECTIVE: To test the validity of the techniques used to calculate quality-adjusted life-year (QALY) values based on utility functions, using a real population dataset.
DESIGN: Using the standard gamble technique, we gathered the preferences of a population sample of 189 individuals on a combination of probabilities concerning four simple health states (no physical disability, limp, walk with crutches and need a wheelchair), and three life-year spans (5, 10 and 15 years). Each of the four assumptions of the multiplicative model was tested based on the results of the experiment.
RESULTS: The utility of the health state "limp" was high at 0.89 and that of "walk with crutches" only slightly lower at 0.85. However, of the 189 individuals, only 57 are not in contradiction with the assumption of mutual utility independence since they strictly preferred (15 years, "need a wheelchair") over (10 years, "need a wheelchair") and (15 years, "need a wheelchair") over (5 years, "need a wheelchair"). For these 57 individuals, the results of this study do not fit the assumptions underpinning the multiplicative model.
CONCLUSION: This work suggests that the techniques used as a basis from which to calculate QALY values are flawed. In particular, the underlying assumptions of the multiattribute utility model do not correspond to behaviour patterns observed in a real population. It therefore appears that use of the QALY technique should be questioned in healthcare decision-making settings.

Mesh:

Year:  2002        PMID: 12093302     DOI: 10.2165/00019053-200220070-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  2 in total

Review 1.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

Review 2.  QALY league tables: handle with care.

Authors:  K Gerard; G Mooney
Journal:  Health Econ       Date:  1993-04       Impact factor: 3.046

  2 in total
  16 in total

1.  Empirical validation of patient versus population preferences in calculating QALYs.

Authors:  Eva-Julia Weyler; Afschin Gandjour
Journal:  Health Serv Res       Date:  2011-04-21       Impact factor: 3.402

2.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

3.  Cost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease.

Authors:  Ariel Beresniak; Thibaut Caruba; Brigitte Sabatier; Yves Juillière; Olivier Dubourg; Nicolas Danchin
Journal:  World J Cardiol       Date:  2015-10-26

4.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

5.  Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Authors:  Ariel Beresniak; Antonieta Medina-Lara; Jean Paul Auray; Alain De Wever; Jean-Claude Praet; Rosanna Tarricone; Aleksandra Torbica; Danielle Dupont; Michel Lamure; Gerard Duru
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

6.  Quality-of-life assessment of fibroid treatment options and outcomes.

Authors:  Fiona M Fennessy; Chung Yin Kong; Clare M Tempany; J Shannon Swan
Journal:  Radiology       Date:  2011-03-01       Impact factor: 11.105

Review 7.  Quality-of-life assessment in rheumatoid arthritis.

Authors:  Anthony S Russell
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

Authors:  S Y Cohen; D Bremond-Gignac; G Quentel; G Mimoun; T Citterio; S Bisot-Locard; A Beresniak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-19       Impact factor: 3.117

9.  Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.

Authors:  Ariel Beresniak; Rafael Ariza-Ariza; Jose Francisco Garcia-Llorente; Antonio Ramirez-Arellano; Danielle Dupont
Journal:  Int J Inflam       Date:  2011-06-28

10.  Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.

Authors:  K Puolakka; H Blåfield; M Kauppi; R Luosujärvi; R Peltomaa; T Leikola-Pelho; K Sennfalt; A Beresniak
Journal:  Open Rheumatol J       Date:  2012-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.